Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Impact · against what's priced in

Helus Pharma (CYBN/HELP) provides positive long-term durability data for HLP003 and confirms the progression of its Phase 3 PARADIGM program. These updates reduce the risk profile for the lead asset by demonstrating 12-month efficacy, which is a critical regulatory hurdle for MDD treatments.

CYBN+0.60

No priced-in read yet